The evaluation of efficacy and safety of sunitinib on EGFR-TKI pretreated advanced non-small cell lung cancer patients in China

Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: Current evidence and future perspectives

(2013) Ana Custodio et al.   CANCER TREATMENT REVIEWS

Regulation of Gene Expression by Progesterone in Cancer Cells: Effects on Cyclin D1, EGFR and VEGF

(2013) Olivia Tania Hernandez-Hernandez et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer

(2012) S. A. Kono et al.   CURRENT CANCER DRUG TARGETS

Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)

(2012) Jin Soo Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial

(2012) Giorgio V. Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer biomarkers: selecting the right drug for the right patient

(2012) Gary J. Kelloff et al.   NATURE REVIEWS DRUG DISCOVERY

Combined EGFR and VEGFR versus Single EGFR Signaling Pathways Inhibition Therapy for NSCLC: A Systematic Review and Meta-Analysis

(2012) Xinji Zhang et al.   PLoS One

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population

(2010) Gu Ping et al.   MEDICAL ONCOLOGY

Targeted Therapies for Non-Small Cell Lung Cancer: An Evolving Landscape

(2010) S. K. Pal et al.   MOLECULAR CANCER THERAPEUTICS

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer

(2009) George R. Blumenschein et al.   JOURNAL OF CLINICAL ONCOLOGY

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

(2009) R. L. Wahl et al.   JOURNAL OF NUCLEAR MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC

(2009) N. A. Pennell et al.   ONCOLOGIST

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

(2008) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

(2008) Edward S Kim et al.   LANCET

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS